Semiotic Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-10-2024
- Paid Up Capital ₹ 0.10 M
as on 23-10-2024
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.01 M
as on 23-10-2024
- Satisfied Charges ₹ 0.80 M
as on 23-10-2024
- Revenue 12.27%
(FY 2023)
- Profit 46.34%
(FY 2023)
- Ebitda 4.58%
(FY 2023)
- Net Worth 29.68%
(FY 2023)
- Total Assets 5.38%
(FY 2023)
About Semiotic Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.01 M. The company has closed loans amounting to ₹0.80 M, as per Ministry of Corporate Affairs (MCA) records.
Satchidanand Dash and Sanjay Dash serve as directors at the Company.
- CIN/LLPIN
U51397OR2014PTC018100
- Company No.
018100
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jul 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Khorda, Odisha, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Semiotic Pharmaceutical?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Dash  | Managing Director | 11-Jul-2014 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Satchidanand Dash | Director | 11-Jul-2014 | Current |
Financial Performance of Semiotic Pharmaceutical.
Semiotic Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.27% increase. The company also saw a substantial improvement in profitability, with a 46.34% increase in profit. The company's net worth Soared by an impressive increase of 29.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Semiotic Pharmaceutical?
In 2022, Semiotic Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 24 Jun 2021 | ₹1.01 M | Open |
Indian Bank Creation Date: 01 Aug 2017 | ₹4.00 M | Open |
Others Creation Date: 12 Jan 2018 | ₹0.80 M | Satisfied |
How Many Employees Work at Semiotic Pharmaceutical?
Semiotic Pharmaceutical has a workforce of 22 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Semiotic Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Semiotic Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
